Olema Pharmaceuticals Inc
For the period ended Jun 30, 2024. Filed Aug 6, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2024 · Filed Aug 6, 2024
OLMA$7.36+0.4%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
| June 30, | December 31, | |
|---|---|---|
| 2024 | 2023 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $16,892 | $68,539 |
| Marketable securities | 222,212 | 193,268 |
| Prepaid expenses and other current assets | 3,083 | 4,706 |
| Total current assets | 242,187 | 266,513 |
| Operating lease right-of-use assets | 1,814 | 2,291 |
| Other assets and long-term deposits | 10,556 | 8,141 |
| Total assets | $254,557 | $276,945 |
| Liabilities and stockholders’ equity | ||
| Current liabilities: | ||
| Accounts payable | $4,354 | $2,698 |
| Operating lease liabilities, current | 1,103 | 988 |
| Other current liabilities | 21,078 | 17,935 |
| Total current liabilities | 26,535 | 21,621 |
| Operating lease liabilities, net of current portion | 859 | 1,429 |
| Total liabilities | 27,394 | 23,050 |
| Commitments and contingencies (Note 10) | ||
| Stockholders’ equity: | ||
| Preferred stock, $0.0001 par value; 10,000,000 shares authorized as of June 30, 2024 and December 31, 2023; no shares issued and outstanding as of June 30, 2024 and December 31, 2023. | — | — |
| Common stock, $0.0001 par value; 490,000,000 shares authorized as of June 30, 2024 and December 31, 2023; 57,258,367 and 55,097,118 shares issued as of June 30, 2024 and December 31, 2023, respectively; 57,246,411 and 54,992,784 shares outstanding as of June 30, 2024 and December 31, 2023, respectively. | 4 | 4 |
| Additional paid-in capital | 594,261 | 559,176 |
| Accumulated other comprehensive (loss) income | (118) | 347 |
| Accumulated deficit | (366,984) | (305,632) |
| Total stockholders’ equity | 227,163 | 253,895 |
| Total liabilities and stockholders’ equity | $254,557 | $276,945 |
Condensed Consolidated Statements of Operations and Comprehensive Loss
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.